ARTICLE | Clinical News

Exenatide once weekly meets DURATION-5 endpoint

December 16, 2009 2:27 AM UTC

Amylin Pharmaceuticals Inc. (NASDAQ:AMLN), Eli Lilly and Co. (NYSE:LLY) and Alkermes Inc. (NASDAQ:ALKS) said exenatide once weekly met the primary endpoint of significantly reducing HbA1c from baseline to week 24 vs. twice-daily Byetta exenatide in the Phase III DURATION-5 trial to treat Type II diabetes (1.6% vs. 0.9%). Exenatide once weekly and Byetta both significantly reduced mean weight loss from baseline to week 24 by 5.1 and 3 pounds, respectively. ...